James Edgemond - May 15, 2024 Form 4 Insider Report for UNITED THERAPEUTICS Corp (UTHR)

Role
CFO AND TREASURER
Signature
/s/ John S. Hess, Jr. under Power of Attorney
Stock symbol
UTHR
Transactions as of
May 15, 2024
Transactions value $
-$4,393,102
Form type
4
Date filed
5/16/2024, 04:30 PM
Previous filing
Nov 9, 2022
Next filing
Aug 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction UTHR Common Stock Options Exercise $4.08M +25K +1584.28% $163.30 26.6K May 15, 2024 Direct F1
transaction UTHR Common Stock Sale -$6.82M -25K -94.06% $272.69 1.58K May 15, 2024 Direct
transaction UTHR Common Stock Options Exercise $2.48M +15.2K +960.71% $163.30 16.7K May 15, 2024 Direct
transaction UTHR Common Stock Sale -$4.13M -15.2K -90.57% $272.69 1.58K May 15, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction UTHR Share Tracking Award Options Exercise $0 -25K -100% $0.00* 0 May 15, 2024 Share Tracking Award 25K $163.30 Direct F2
transaction UTHR Share Tracking Award Options Exercise $0 -15.2K -100% $0.00* 0 May 15, 2024 Share Tracking Award 15.2K $163.30 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 26, 59, 47, and 62 shares of common stock acquired on September 2, 2022, March 3, 3023, September 1, 2023, and March 4, 2024, respectively, under the United Therapeutics Corporation Employee Stock Purchase Plan.
F2 Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.